Related Experiment Video

Updated: Jun 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Angiogenesis inhibition in prostate cancer: current uses and future promises

Jeanny B Aragon-Ching1, Ravi A Madan, William L Dahut

  • 1Division of Hematology and Oncology, Department of Medicine, The George Washington University Medical Center, 2150 Pennsylvania Avenue Northwest, Washington, DC 20037, USA.

Journal of Oncology
|February 20, 2010
PubMed

Insights

Angiogenesis, the growth of new blood vessels, is crucial for cancer progression. Antiangiogenic therapies targeting vascular endothelial growth factor (VEGF) show promise for prostate cancer, but resistance and response assessment remain challenges.

Area of Science:

  • Oncology
  • Cancer Biology
  • Medical Research

Background:

  • Angiogenesis is a critical process in cancer development, enabling tumor growth, invasion, and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) and its receptors are key targets for antiangiogenic cancer therapies.
  • Numerous antiangiogenic drugs targeting VEGF are approved for various solid tumors, demonstrating established therapeutic efficacy.

Purpose of the Study:

  • To explore the role and therapeutic potential of antiangiogenesis agents in prostate cancer.
  • To review the current landscape of antiangiogenic therapies in oncology.
  • To address the challenges of resistance and response assessment in antiangiogenic treatment.

Main Methods:

  • Review of existing literature on angiogenesis inhibitors and their application in cancer treatment.
  • Analysis of the role of angiogenesis in prostate cancer progression.
  • Exploration of the clinical promise and challenges of antiangiogenic agents in prostate cancer.

Main Results:

  • Antiangiogenic strategies, particularly those targeting VEGF, are a significant area of cancer research with approved therapies.
  • Angiogenesis is implicated in the progression of prostate cancer.
  • While promising, antiangiogenic therapies face challenges in overcoming resistance and accurately assessing patient response.

Conclusions:

  • Antiangiogenesis is a validated therapeutic strategy in oncology.
  • Further research is needed to overcome resistance and improve response assessment for antiangiogenic therapies in prostate cancer.
  • Targeting angiogenesis holds significant promise for the management of prostate cancer.

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...